At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 40 enrolled
Drug / intervention
PPX with cisplatin and radiationdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
BrUOG-E-215-Neoadjuvant Paclitaxel Poliglumex (PPX; CT-2103), Cisplatin and Radiation for Esophageal Cancer: A Phase II Trial. (CTI#X64001
In Brief
A Phase 2 clinical trial evaluating PPX with cisplatin and radiation for Esophageal Cancer. Completed, enrolled 40 participants across 1 site.
Detailed Summary
Neoadjuvant Paclitaxel Poliglumex (PPX; CT-2103), Cisplatin and Radiation for Esophageal Cancer: A Phase II Trial. (CTI#X64001
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEsophageal Cancer
CountriesUnited States
CollaboratorsUniversity of Maryland Greenebaum Cancer Center
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2007
First PostedAug 2007
Primary CompletionFeb 2010
Study CompletionApr 2010
TodayJul 2026
First PostedAug 30, 2007
Enrollment StartAug 1, 2007
Primary CompletionFeb 1, 2010
Study CompletionApr 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 18.8 years ago
Interventions
PPX with cisplatin and radiationdrug
weekly IV treatment of Paclitaxel Poliglumex and Cisplatin for 6 weeks